Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Xetra  >  Sartorius AG (Preference)    SRT3   DE0007165631

Analysis summary4-Traders Strategies 

German pharma-supplier combining growth and profitability

share with twitter share with LinkedIn share with facebook
share via e-mail
03/17/2017 | 09:23am

Advanced Medical Equipment & Technology

Sartorius is a leading international pharmaceutical and laboratory equipment supplier with projected annual revenue growth of between 8% and 12%. The company comprises two divisions: Bioprocess Solutions & Lab Products and Services.

Sartorius’ innovative products and services are helping customers across the entire globe to implement their often complex biomanufacturing and laboratory processes.

The Group companies are united under the roof of Sartorius AG, which is listed on the Frankfurt Stock Exchange and holds the majority stake (74%) in Sartorius Stedim Biotech S.A. Quoted on the Paris Stock Exchange, this subgroup is comprised mainly of the Bioprocess Solutions Division.

With about 50 sites (19 of which are production facilities) employing 6.900 people
in more than 30 countries Sartorius is a global player. Its products are available in more than 110 countries. The company is run from the global headquarter in Göttingen, Germany.
Sales are well diversified geographically as shown by the following graph.

The growth prospects for Sartorius’ profit are excellent benefitting from three principal growth drivers:

- Strong overall market growth in bioprocessing and to a lesser degree pharmaceuticals
- Market share gains, particularly in the Americas
- Economies of scale

Background Information

To put it in a nutshell, Sartorius seeks to pave the way for researchers and scientists to focus on their ideas and innovations. To this end, Sartorius has created a very broad product offering providing clients with a one-stop shop solution. In its lab products and services category, products are grouped as follows: weighing, quality control, lab water purification, liquid handling, cell cultivation, filtration and purification.
The Bioprocess Solutions Divisions comprises five product groups: Filtration and purification, process control, fluid management, media and buffers, fermentation and cell culture.
Altogether, the company offers hundreds of different kinds of equipment.

Investment Case

The investment case for Sartorius is straight-forward. The company is firing on all cylinders. Thanks to the above-mentioned growth drivers, Sartorius’ revenue is forecast to progress at a low double digit percentage rate for the foreseeable future while the bottom line is expected to grow even faster as a consequence of the realization of economies of scale. Already, Sartorius is highly profitable as evidenced by a ROE of 22%.

The following list sums up the key points of our investment case:

➢ Buoyant revenue and earnings growth
➢ Very strong profitability which continues to improve

➢ Sartorius’ extremely broad product portfolio provides a one-stop shop solution thereby cutting out potential competitors
➢ Long-term strategic approach as evidenced by significant investment in R&D


At the current share price, the company is fairly priced in our view. Investors have priced in the growth rates the company is expecting to see over the next couple of years. However, the analysts at Commerzbank see more value in the stock at the current price level. On 8 March 2017, Commerzbank increased its price target for Sartorius from 72 Euro to 90 Euro with the analyst Daniel Wendorff arguing that the acquisition of US company Essen BioScience would boost growth significantly.
In any case long-term investors should seize the opportunity to establish a position in the stock whenever a material pullback in Sartorius’ stock price occurs.

Ulrich Ebensperger
© Zonebourse.com 2017
share with twitter share with LinkedIn share with facebook
share via e-mail

Disclaimer: 4-traders.com is a website published by SURPERFORMANCE SAS. Surperformance or 4-traders.com is not a registered broker-dealer nor a registered investment adviser. You understand that this web site and its content is furnished for your personal, noncommercial, informational purposes only, and that no mention of a particular security in this website constitutes a recommendation to buy, sell, or hold any other security, nor that any particular security, portfolio of securities, transaction or investment strategy is suitable for any specific person. Surperformance and 4-traders.com services will not advise you personally concerning the nature, potential, value or suitability of any particular security, portfolio of securities, transaction, investment strategy or other matter. Information regarding trading and investment as provided by Surperformance professional is not tailored to the investment needs of any specific person. You acknowledge that you are responsible for your own financial decisions and should seek a registered financial agent depending on your own risk tolerance to advise you on your personal trading activities.

Operates as an international laboratory and process technology provider for the biotech, pharmaceutical and food industriesSartorius AG is an international laboratory and process technology provider for the biotech, pharmaceutical, and food industries.It operates through the Bioprocess Solutions... 
More about the company
Financials (€)
Sales 2015 1 031 M
EBIT 2015 170 M
Net income 2015 79,9 M
Debt 2015 284 M
Yield 2015 1,67%
P/E ratio 2015 18,43
P/E ratio 2016 16,93
EV / Sales 2015 6,64x
EV / Sales 2016 6,15x
Capitalization 6 568 M
More Financials
Duration : Period : Day
Sartorius AG (Preference) Technical Analysis Chart | SRT3 | DE0007165631 | 4-Traders
Duration : Period : Week
Sartorius AG (Preference) Technical Analysis Chart | SRT3 | DE0007165631 | 4-Traders
Surperformance© ratings  Help  
Fundamental ratings
Overall rating
Trading Rating
Investor Rating
Growth (Revenue)
Earnings quality
Business Predictability
P/E ratio
7 days EPS revision
4 months EPS revision
1 year EPS revision
4 months Revenue revision
1 year Revenue revision
Technical ratings
Short Term Timing
Middle Term Timing
Long Term Timing
Bollinger Spread
Unusual Volumes
More Ratings